Opinion|Videos|March 11, 2024
Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
Carol Ann Huff, MD, describes her institution's multidisciplinary approach to monitoring for adverse events when administering bispecific antibodies, including the roles of nurses, pharmacists, and attending physicians.
Advertisement
Advertisement
Related to this article
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
5